Table 5.
Drugs of clinical trials for the components in Wnt/β-catenin signaling pathway.
| Description of Mode of Action | Drugs | Cancer Type | Drug Progression | Identifier (NCT Number) |
References |
|---|---|---|---|---|---|
| CBP/β-catenin antagonist | PRI-724 | Advanced pancreatic cancer Metastatic pancreatic cancer Pancreatic adenocarcinoma Advanced solid tumors |
Phase 1 |
NCT01764477 NCT01302405 NCT01606579 |
[157] |
| PRI-724 (with Leucovorin Calcium, Oxaliplatin, or Fluorouracil) | Acute myeloid leukemia Chronic myeloid leukemia |
Phase 2 | NCT02413853 | [158] | |
| FZD10 antagonist |
OTSA101-DTPA-90Y | Sarcoma Synovial |
Phase 1 | NCT01469975 | [159] |
| FZD8 decoy receptor (Fusion protein of FZD8 and IgG Fc domain competing with native FZD8 receptor) |
OMP-54F28 | Solid tumors | Phase 1 | NCT01608867 | [160] |
| OMP-54F28 (with Nab-Paclitaxel and Gemcitabine) | Pancreatic cancer Stage IV pancreatic cancer |
Phase 1 | NCT02050178 | [161] | |
| OMP-54F28 (with Paclitaxel and Carboplatin) | Ovarian cancer | Phase 1 | NCT02092363 | [162] | |
| OMP-54F28 (with Sorafenib) | Hepatocellular cancer Liver cancer |
Phase 1 | NCT02069145 | [163] | |
| Monoclonal antibody against FZD receptors | OMP-18R5 | Metastatic breast cancer Solid tumors |
Phase 1 |
NCT01973309 NCT01345201 |
[164] |
| OMP-18R5 (with Docetaxel) | Solid tumors | Phase 1 | NCT01957007 | [165,166] | |
| OMP-18R5 (with Nab-Paclitaxel and Gemcitabine) | Pancreatic cancer Stage IV pancreatic cancer |
Phase 1 | NCT02005315 | [167] | |
| Porcupine inhibitors |
CGX1321 | Colorectal adenocarcinoma Gastric adenocarcinoma Pancreatic adenocarcinoma Bile duct carcinoma Hepatocellular carcinoma Esophageal carcinoma Gastrointestinal cancer |
Phase 1 | NCT03507998 | [168] |
| CGX1321 (with Pembrolizumab) | Solid tumors GI cancer |
Phase 1 | NCT02675946 | [169] | |
| ETC-1922159 | Solid tumor | Phase 1 | NCT02521844 | [170] | |
| RXC004 | Solid tumor | Phase 1 | NCT03447470 | [171] | |
| WNT974 | Squamous cell cancer Head and Neck |
Phase 2 |
NCT02649530 NCT01351103 |
[172] | |
| WNT974 (with LGX818 and Cetuximab) | Metastatic colorectal carcinoma |
Phase 1 | NCT02278133 | [173] | |
| β-catenin-controlled gene expression inhibitor |
SM08502 | Solid tumors | Phase 1 | NCT03355066 | [174] |
| Wnt signaling pathway inhibitor |
SM04690 | Osteoarthritis | Phase 2 | NCT02536833 | [175] |
| SM04755 | Tendinopathy | Phase 1 | NCT03229291 | [176] |